Amendment to exclusive patent, know-how and technology to make, have made, use, sell, offer, export, import, label, package and sublicense products related to LHRH antagonist compounds for all human therapeutic, prophylactic and diagnostic uses, including prostrate cancer and endometriosis indications, but excluding veterinary uses.

The document serves as a legal amendment to an exclusive patent and technology license for LHRH antagonist compounds, granting rights for manufacturing, selling, and sublicensing products across various human therapeutic and diagnostic applications. The text explicitly lists prostate cancer and endometriosis as specific indications covered by this agreement while excluding veterinary uses from the scope of the licensed intellectual property. RoyaltyStat is referenced as a database used by professionals in transfer pricing and finance to analyze such licensing agreements and royalty rates. Relevance to endometriosis: listed as one indication for LHRH antagonists within the context of a patent amendment, though the paper's main focus is on intellectual property law and royalty analytics.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works